¿Cuál es el beneficio cardiovascular de arGLP-1 vs. iSGLT2 en diabetes tipo 2?

Respuesta generada por Itaca · 56 fuentes · 13 de febrero de 2026

Pregunta original

Resume y compara los resultados de ensayos clínicos sobre GLP-1 vs. SGLT2 en la reducción del riesgo cardiovascular en pacientes con diabetes tipo 2

Comparative Analysis of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Risk Reduction for Type 2 Diabetes: A Comprehensive Review of Clinical Trial Evidence

Over the past decade, two major classes of glucose-lowering agents—glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2i)—have fundamentally transformed the management of type 2 diabetes beyond glycemic control alone, demonstrating substantial reductions in major adverse cardiovascular events (MACE) and modifications in cardiorenal outcomes through distinct mechanistic pathways. A comprehensive meta-analysis examining twelve randomized controlled trials involving 99,261 high-risk patients with type 2 diabetes reveals that both drug classes significantly reduce MACE compared to placebo, with indirect comparisons indicating a nominally greater MACE reduction with GLP-1 RAs (hazard ratio 1.09, 95% CI 1.00–1.18; p = 0.0497), yet SGLT2i demonstrate pronounced advantages in reducing hospitalization for heart failure (HR 0.68) and composite renal outcomes (HR 0.69), while GLP-1 RAs exhibit superior benefits for atherosclerotic events and weight loss[1][2]. These markedly different secondary outcome profiles underscore that while both classes represent significant cardiovascular breakthroughs, they are complementary rather than interchangeable, with optimal therapy selection depending on individual patient phenotypes, baseline comorbidities, and predominant cardiovascular or renal risk profiles.

Glucagon-Like Peptide-1 Receptor Agonist Trials and Cardiovascular Efficacy

SUSTAIN-6: Semaglutide and Cardiovascular Outcomes

The Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) represents a landmark cardiovascular outcomes trial that established the class benefits of long-acting GLP-1 receptor agonists in high-risk populations[3]. This trial enrolled 3,297 patients with type 2 diabetes and either established cardiovascular disease or multiple cardiovascular risk factors, with 83 percent of patients having established cardiovascular disease, chronic kidney disease, or both at baseline. Participants were randomized to receive once-weekly subcutaneous semaglutide (0.5 mg or 1.0 mg) or placebo in addition to standard care over a median follow-up period of approximately 2 years. The primary composite outcome was defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. The results demonstrated that the composite primary outcome occurred in 108 of 1,648 patients (6.6 percent) in the semaglutide group compared to 146 of 1,649 patients (8.9 percent) in the placebo group, yielding a hazard ratio of 0.74 (95 percent CI 0.58 to 0.95; P less than 0.001 for non-inferiority), representing a 26 percent relative risk reduction[3]. Notably, nonfatal myocardial infarction occurred in 2.9 percent of patients receiving semaglutide versus 3.9 percent of those receiving placebo, and the trial demonstrated consistent benefits across prespecified subgroups including those defined by baseline cardiovascular disease status and renal function.

Secondary analyses of SUSTAIN-6 data examined potential mediators of the cardiovascular benefits observed with liraglutide, another GLP-1 receptor agonist, using the LEADER trial cohort of 9,340 patients with type 2 diabetes and high cardiovascular risk[4]. These mediation analyses, conducted using Cox proportional hazards methods and the newer Vansteelandt method, revealed that hemoglobin A1c (HbA1c) reduction appeared to be the most promising candidate as a potential mediator of the cardiovascular benefit, accounting for approximately 82 percent of the total observed cardiovascular benefit of liraglutide on major adverse cardiovascular events at three years (95 percent CI 11.7; 449.3), with the direct effect of liraglutide accounting for the remaining 18 percent of the total observed cardiovascular benefit[4]. When additional variables including body weight, urine albumin-to-creatinine ratio, systolic blood pressure, LDL cholesterol, confirmed hypoglycemic episodes, sulfonylurea use, and insulin use were included as confounders in the model, the indirect effect of liraglutide on MACE mediated by HbA1c was estimated to be 69.2 percent, which remained consistent with the unconfounded analysis considering the uncertainty in the estimates. This mechanistic understanding suggests that while GLP-1 receptor agonists exert direct anti-inflammatory and antiatherogenic effects, a substantial proportion of their cardiovascular benefits derive from improvements in glycemic control.

LEADER Trial: Liraglutide Efficacy and Action in Diabetes

The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial enrolled 9,340 patients with type 2 diabetes and high cardiovascular risk, defined as either established cardiovascular disease or at least two cardiovascular risk factors[4][5]. Patients were randomized to receive daily liraglutide versus placebo in addition to existing diabetes care. Among the 9,340 randomized participants, 76 percent used metformin at baseline, and the study followed patients for a median of 3.7 years. The primary outcome was time from randomization to the first occurrence of a composite of cardiovascular death, myocardial infarction, or stroke. In a prespecified analysis examining background metformin use, liraglutide did not significantly reduce the incidence of the primary outcome versus placebo among baseline metformin users (hazard ratio 0.97, 95 percent CI 0.85–1.10) but did reduce incidence among baseline metformin nonusers (hazard ratio 0.79, 95 percent CI 0.64–0.97)[5]. This finding raised important questions about the potential influence of background antidiabetic therapy on the cardiovascular efficacy of GLP-1 receptor agonists and led to subsequent guidance from the European Society of Cardiology recommending GLP-1 receptor agonists as first-line treatment for patients with type 2 diabetes at high cardiovascular risk, potentially independent of metformin use.

SELECT Trial: Semaglutide in Obese Patients Without Diabetes

The SELECT trial extended the cardiovascular benefits of GLP-1 receptor agonists beyond the traditional diabetes population by evaluating semaglutide in 17,604 overweight or obese patients with prior cardiovascular disease but without diabetes mellitus[6][7]. This multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial conducted at 804 clinical sites in 41 countries enrolled patients with a mean age of 61.6 years, with 72.3 percent males, a mean body mass index of 33.3 ± 5.0, and prior myocardial infarction in 75 percent of participants, with 25 percent having a history of heart failure. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo, with a mean exposure of 34.2 ± 13.7 months. The primary cardiovascular efficacy endpoint was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, assessed in a time-to-first-event analysis. The SELECT trial resulted in major adverse cardiovascular events (MACE) in 6.5 percent of the semaglutide group versus 8.0 percent of the placebo group, corresponding to a hazard ratio of 0.80 (95 percent CI 0.72–0.90; p less than 0.001), representing a 20 percent reduction in the risk of cardiovascular outcomes and a 17 percent relative risk reduction for mortality[6][7]. Importantly, this benefit was achieved in a population without diabetes, with 66.4 percent of participants having prediabetes at baseline (HbA1c 5.7–6.4 percent), suggesting that the cardiovascular protective effects of GLP-1 receptor agonists extend beyond their glucose-lowering properties.

The prespecified subgroup analyses of the SELECT trial primary outcome revealed heterogeneity based on baseline characteristics, with hazard ratios of 0.84 (95 percent CI 0.66–1.07) for female versus 0.79 (95 percent CI 0.70–0.90) for male patients, 0.82 (95 percent CI 0.68–1.00) for HbA1c less than 5.7 percent versus 0.79 (95 percent CI 0.69–0.90) for HbA1c greater than or equal to 5.7 percent, and notably 0.72 (95 percent CI 0.60–0.87) for patients with heart failure versus 0.84 (95 percent CI 0.74–0.97) for those without heart failure. The study drug discontinuation rate was twice as common in the semaglutide arm, primarily due to gastrointestinal intolerance, a known side effect of GLP-1 receptor agonists. Body weight reduction in the semaglutide group was 9.39 percent at week 104 compared to 0.88 percent in the placebo arm, with subsequent analysis showing a sustained mean weight reduction of 10.2 percent at week 208 compared to only 1.5 percent of the placebo group.

Sodium-Glucose Cotransporter-2 Inhibitor Trials and Cardiovascular Efficacy

EMPA-REG OUTCOME: Empagliflozin Cardiovascular Outcome Event Trial

The EMPA-REG OUTCOME trial was the first major cardiovascular outcomes trial demonstrating the benefits of an SGLT2 inhibitor and fundamentally changed the understanding of this drug class beyond glucose-lowering effects[8][9]. This trial randomized 7,020 patients with type 2 diabetes and established cardiovascular disease in a 1:1:1 fashion to either empagliflozin 10 mg (n=2,345), empagliflozin 25 mg (n=2,342), or matching placebo (n=2,333). The total number of enrollees was 7,028, with a mean age of 63.1 years, 28 percent female, and a mean follow-up duration of 3.1 years. The primary composite outcome was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The primary outcome occurred in 10.5 percent of the pooled empagliflozin group (490 of 4,687 patients) and 12.1 percent of the placebo group (282 of 2,333 patients), yielding a hazard ratio in the empagliflozin group of 0.86 (95 percent CI 0.74–0.99; P=0.04 for superiority)[9]. Remarkably, there were significantly lower rates of death from cardiovascular causes in the empagliflozin group (3.7 percent versus 5.9 percent in the placebo group; 38 percent relative risk reduction), hospitalization for heart failure (2.7 percent versus 4.1 percent respectively; 35 percent relative risk reduction), and death from any cause (5.7 percent versus 8.3 percent respectively; 32 percent relative risk reduction)[9]. However, there were no significant between-group differences in the rates of myocardial infarction or stroke individually. The cardiovascular death reduction observed in EMPA-REG OUTCOME is notably striking compared to other cardiovascular outcomes trials and has been attributed to the diuretic and hemodynamic effects of SGLT2 inhibition in the context of heart failure prevention.

DECLARE-TIMI 58: Dapagliflozin and Cardiovascular Outcomes

The DECLARE-TIMI 58 trial evaluated dapagliflozin, another SGLT2 inhibitor, in approximately 17,160 patients with type 2 diabetes, with approximately 40.6 percent having established atherosclerotic cardiovascular disease and 59.4 percent having multiple risk factors[10][11]. This superiority trial was designed to test the hypothesis that long-term treatment with dapagliflozin would reduce either the incidence of cardiovascular death, myocardial infarction, or ischemic stroke, or the incidence of cardiovascular death or hospitalization for heart failure. The trial randomized patients 1:1 to receive 10 mg dapagliflozin or placebo once daily. As previously reported, the cardiorenal secondary composite outcome was significantly reduced with dapagliflozin versus placebo (hazard ratio 0.76, 95 percent CI 0.67–0.87; p less than 0.0001), and excluding death from cardiovascular causes, the hazard ratio for the renal-specific outcome was 0.53 (0.43–0.66; p less than 0.0001)[10]. The trial identified a 46 percent reduction in sustained decline in estimated glomerular filtration rate by at least 40 percent to less than 60 mL/min per 1.73m² (1.4 percent versus 2.6 percent; hazard ratio 0.54, 95 percent CI 0.43–0.67; p less than 0.0001). The risk of end-stage renal disease or renal death was lower in the dapagliflozin group than in the placebo group (0.1 percent versus 0.3 percent; hazard ratio 0.41, 95 percent CI 0.20–0.82; p=0.012). Both the cardiorenal and renal-specific composite outcomes were improved with dapagliflozin versus placebo across various prespecified subgroups, including those defined by baseline estimated glomerular filtration rate and the presence or absence of established atherosclerotic cardiovascular disease. Six months after randomization, the mean decrease in estimated glomerular filtration rate was larger in the dapagliflozin group than in the placebo group, but the mean change equalized by 2 years, and at 3 and 4 years the mean decrease in estimated glomerular filtration rate was less with dapagliflozin than with placebo.

CANVAS Program: Canagliflozin and Cardiovascular and Renal Events

The CANVAS Program integrated data from two trials (CANVAS and CANVAS-R) involving a total of 10,142 participants with type 2 diabetes and high cardiovascular risk, with a mean age of 63.3 years, 35.8 percent women, mean diabetes duration of 13.5 years, and 65.6 percent with a history of cardiovascular disease[12]. Participants in each trial were randomly assigned to receive canagliflozin or placebo and were followed for a mean of 188.2 weeks. The primary outcome was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The rate of the primary outcome was lower with canagliflozin than with placebo (occurring in 26.9 versus 31.5 participants per 1,000 patient-years; hazard ratio 0.86, 95 percent CI 0.75–0.97; P less than 0.001 for non-inferiority; P=0.02 for superiority)[12]. Although on the basis of the prespecified hypothesis testing sequence the renal outcomes are not viewed as statistically significant, the results showed a possible benefit of canagliflozin with respect to the progression of albuminuria (hazard ratio 0.73, 95 percent CI 0.67–0.79) and the composite outcome of a sustained 40 percent reduction in the estimated glomerular filtration rate, the need for renal-replacement therapy, or death from renal causes (hazard ratio 0.60, 95 percent CI 0.47–0.77). A notable adverse finding was an increased risk of amputation (6.3 versus 3.4 participants per 1,000 patient-years; hazard ratio 1.97, 95 percent CI 1.41–2.75), with amputations primarily at the level of the toe or metatarsal, which has necessitated careful patient selection and monitoring with this specific SGLT2 inhibitor.

Comparative Efficacy: Head-to-Head Evidence and Indirect Comparisons

Meta-Analytical Comparisons of MACE Reduction

A comprehensive meta-analysis comparing twelve randomized controlled trials with 99,261 high-risk participants with type 2 diabetes demonstrated that both SGLT2 inhibitors and GLP-1 receptor agonists significantly reduced major adverse cardiovascular events compared with placebo[1][2]. When compared to placebo, SGLT2 inhibitors significantly reduced MACE with a hazard ratio of 0.89 (95 percent CI 0.84–0.95; p = 0.0003), and GLP-1 receptor agonists reduced MACE with a hazard ratio of 0.82 (95 percent CI 0.78–0.87; p less than 0.00001)[1][2]. The indirect comparison of these two drug classes indicated a nominally greater MACE reduction with GLP-1 receptor agonists (hazard ratio 1.09, 95 percent CI 1.00–1.18; p = 0.0497), suggesting approximately a 9 percent greater MACE reduction with GLP-1 receptor agonists compared to SGLT2 inhibitors[1][2]. However, this difference must be interpreted with caution as it represents an indirect comparison and does not reflect any head-to-head randomized controlled trial evidence comparing these two classes directly in the same population.

The certainty of the evidence for both drug classes, assessed using the GRADE framework, was rated as high for the reduction in major adverse cardiovascular events[1][2]. This high rating was based on consistent results from randomized trials with a low risk of bias, negligible statistical heterogeneity, direct applicability to clinical populations, precise effect estimates, and no suspected publication bias. The consistency of these findings across multiple trials representing diverse patient populations with varying baseline characteristics, comorbidities, and geographic locations strengthens the evidence for both classes of medications in cardiovascular risk reduction.

Differential Secondary Outcomes: Heart Failure, Renal Protection, and Atherosclerotic Benefits

The most clinically salient distinction between SGLT2 inhibitors and GLP-1 receptor agonists emerges in their secondary outcome profiles, which reveal markedly different phenotypic benefits critical for therapy selection. SGLT2 inhibitors demonstrated a pronounced advantage in reducing hospitalization for heart failure (hazard ratio 0.68, 95 percent CI 0.61–0.76; p less than 0.00001) compared to placebo[1][2], with no heterogeneity across trials (I² = 0 percent; p = 0.85). In contrast, GLP-1 receptor agonists provided more modest but significant benefits on heart failure hospitalizations (hazard ratio 0.88, 95 percent CI ranging approximately 0.80–0.97), representing a 12 percent risk reduction compared to the 32 percent risk reduction observed with SGLT2 inhibitors. Similarly, for composite renal outcomes, SGLT2 inhibitors demonstrated a significant reduction (hazard ratio 0.69, 95 percent CI 0.62–0.77; p less than 0.00001) with moderate heterogeneity (I² = 49 percent; p = 0.10), while GLP-1 receptor agonists showed more modest renal benefits (hazard ratio 0.76, 95 percent CI ranging approximately 0.68–0.86), representing a 24 percent risk reduction compared to the 31 percent risk reduction with SGLT2 inhibitors.

Conversely, GLP-1 receptor agonists demonstrated more pronounced benefits for atherosclerotic cardiovascular events, particularly in stroke prevention[13]. The American Stroke Association has incorporated GLP-1 receptor agonists into its guidelines for stroke prevention based on compelling data from cardiovascular outcomes trials demonstrating significant reductions in non-fatal stroke rates. Meta-analyses of eight cardiovascular outcome trials have revealed an overall 14 percent reduction in major adverse cardiovascular events with GLP-1 therapy, with specific reductions in cardiovascular death (13 percent), non-fatal stroke (16 percent), and non-fatal myocardial infarction (9 percent)[13]. The highest percentage reduction was observed in non-fatal stroke prevention, representing a distinct advantage of this drug class. Additionally, GLP-1 receptor agonists consistently demonstrated superior weight loss compared to SGLT2 inhibitors, with weight reductions typically ranging from 10 to 15 percent depending on the specific GLP-1 agent and trial population, compared to more modest weight losses of 2 to 4 percent observed with SGLT2 inhibitors.

Mechanistic Pathways Underlying Cardiovascular Benefits

GLP-1 Receptor Agonist Mechanisms

GLP-1 receptor agonists exert their cardiovascular protective effects through multiple complementary mechanisms that extend beyond glucose lowering[14][15]. These medications activate the GLP-1 receptor expressed in pancreatic beta cells, promoting glucose-dependent insulin secretion, but also act on extrapancreatic sites including hypothalamic neurons to reduce appetite and promote weight loss, on the gastrointestinal tract to slow gastric emptying and reduce postprandial glucose excursions, and potentially on the heart and vasculature through both direct and indirect mechanisms. The cardiovascular risk reduction achieved with GLP-1 receptor agonists results from improvements in multiple risk factors including glycemic control, body weight reduction, blood pressure reduction of approximately 2 to 3 millimeters of mercury, improvements in postprandial lipemia and circulating triglyceride levels, and reductions in inflammatory markers such as high-sensitivity C-reactive protein. GLP-1 receptor agonists reduce hepatic steatosis and circulating triacylglycerol and LDL cholesterol levels through actions that require a functional GLP-1 receptor.

Beyond these traditional cardiovascular risk factors, GLP-1 receptor agonists exhibit direct anti-inflammatory and antiatherogenic effects[15]. These agents reduce vascular inflammation, decrease apoptosis in endothelial cells, enhance endothelial function and flow-mediated vasodilatation of the brachial artery, and may decrease clumping of blood platelets, thereby reducing the risk of thrombotic events and stroke. The mechanistic interpretation of these findings has been complicated by the failure to control for simultaneous GLP-1 receptor agonist-mediated increases in insulin levels and reductions in glycemia, suggesting that the full spectrum of cardiovascular benefits likely results from multifactorial effects on the central nervous system, peripheral vasculature, heart, and systemic metabolism.

SGLT2 Inhibitor Mechanisms

SGLT2 inhibitors exert their cardiovascular and renal protective effects primarily through hemodynamic and metabolic mechanisms that are distinct from their glucose-lowering properties, explaining why these benefits extend to patients without diabetes[16][17]. These agents block the sodium-glucose cotransporter-2 in the proximal tubule of the kidney, reducing glucose and sodium reabsorption and leading to natriuresis and osmotic diuresis that decrease cardiac preload and afterload, alleviate increased intraglomerular pressure, and exert downstream effects on blood pressure. The natriuretic effects of SGLT2 inhibitors occur via proximal tubule Na⁺/H⁺ exchanger NHE3 inhibition, and these diuretic actions contribute to rapid symptomatic improvement in heart failure patients observed within days to weeks of treatment initiation.

Beyond hemodynamic effects, SGLT2 inhibitors modulate neurohumoral pathways with evidence of attenuated sympathetic activity, stimulate erythropoiesis leading to improved oxygenation of ischemic tissues particularly in the context of local hypoxia and systemic inflammation with iron regulation effects, mitigate the hyperuricemic environment in cardiorenal syndromes through increased uricosuria, and induce multiorgan metabolic reprogramming including induction of a fasting-like state, improvement in glucose and insulin tolerance, stimulation of lipolysis and ketogenesis, and upregulation of vascular endothelial growth factor A with consequent angiogenesis[16][17]. At the cellular level, SGLT2 inhibitors suppress the energy-sensitive mTORC1-signaling pathway in kidney tubules, restoring metabolic perturbations toward normal, reducing glycolysis and gluconeogenesis in proximal tubular cells while the reverse occurs in distal segments such as the medullary thick ascending limb. These complex cellular mechanisms explain why SGLT2 inhibitors provide rapid and sustained benefits to patients with heart failure regardless of diabetes status and why these medications have demonstrated efficacy in advanced chronic kidney disease.

Efficacy in Specific Clinical Phenotypes

Heart Failure Populations

The distinct cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists become particularly evident in heart failure populations, where treatment selection should be tailored to the predominant phenotype. SGLT2 inhibitors have demonstrated remarkable efficacy in reducing hospitalizations for heart failure in both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF), with relative risk reductions of approximately 30 to 40 percent observed across multiple trials[18]. A meta-analysis of approximately 17,000 heart failure patients demonstrated that SGLT2 inhibitors significantly reduced the composite of first heart failure hospitalization or cardiovascular death (hazard ratio 0.77, 95 percent CI 0.72–0.83; P less than 0.001; I² = 0 percent) and first heart failure hospitalization alone (hazard ratio 0.71, 95 percent CI 0.64–0.78; P less than 0.001; I² = 0 percent)[18]. These findings remained consistent when the HFrEF population was analyzed separately, with a hazard ratio of 0.72 (95 percent CI 0.66–0.79) for the composite of first heart failure hospitalization or cardiovascular death and 0.69 (95 percent CI 0.62–0.76) for first heart failure hospitalization. A trend towards better heart failure hospitalization-related outcomes was observed in the HFpEF subpopulation, though this finding should be considered exploratory rather than definitive due to scarce and heterogeneous data.

In contrast, GLP-1 receptor agonists demonstrate safety and clinical benefit in heart failure populations, with favorable effects on cardiovascular outcomes and all-cause mortality[19]. In a real-world observational study comparing GLP-1 receptor agonist users with dipeptidyl peptidase-4 inhibitor users among patients with type 2 diabetes and heart failure with reduced ejection fraction over a 5-year follow-up period, GLP-1 receptor agonist therapy was associated with a significantly reduced hazard ratio for all-cause mortality (0.62, 95 percent CI 0.59–0.66; P less than 0.001), representing a 38 percent reduction in mortality and an absolute risk reduction of 11.0 percent (13.3 percent versus 24.3 percent), with a number needed to treat of 9.1[19]. These findings suggest that while SGLT2 inhibitors represent the cornerstone therapy for heart failure management due to their pronounced effects on hospitalization reduction, GLP-1 receptor agonists provide important complementary mortality benefits and are increasingly recognized as valuable adjunctive therapy in heart failure populations. The subgroup analyses of the SELECT trial examining patients with heart failure demonstrated a hazard ratio of 0.72 (95 percent CI 0.60–0.87) for MACE in heart failure patients receiving semaglutide versus placebo, compared to 0.84 (95 percent CI 0.74–0.97) in those without heart failure, suggesting that patients with heart failure may experience enhanced cardiovascular benefit from GLP-1 receptor agonist therapy.

Chronic Kidney Disease Populations

The comparative efficacy of SGLT2 inhibitors and GLP-1 receptor agonists in chronic kidney disease populations has been the subject of extensive investigation, with consistent evidence suggesting superiority of SGLT2 inhibitors for slowing chronic kidney disease progression. A recent comparative effectiveness study using nationwide, population-based data from Denmark with target trial emulation design included 36,279 individuals who initiated an SGLT2 inhibitor and 18,782 who initiated a GLP-1 receptor agonist, with comparable diabetes duration, estimated glomerular filtration rate, and urine albumin-to-creatinine ratios[20]. The weighted 5-year risk of chronic kidney disease, defined as a sustained 40 percent reduction in estimated glomerular filtration rate, severe albuminuria, or kidney failure, was 6.7 percent (95 percent CI 6.4–7.0 percent) for SGLT2 inhibitor initiators and 8.2 percent (95 percent CI 7.8–8.6 percent) for GLP-1 receptor agonist initiators, yielding a risk ratio of 0.81 (95 percent CI 0.76–0.87) and a risk difference of minus 1.5 percent (95 percent CI minus 2.0 to minus 1.0 percent)[20]. The 5-year mean cumulative count of acute kidney injury per 100 individuals was 25.2 (95 percent CI 24.4–26.1) for SGLT2 inhibitor initiators and 28.7 (95 percent CI 27.4–30.0) for GLP-1 receptor agonist initiators, with a mean cumulative count ratio of 0.88 (95 percent CI 0.83–0.93) and a mean cumulative count difference of minus 3.5 (95 percent CI minus 5.0 to minus 2.0), demonstrating that SGLT2 inhibitors provide superior protection against both chronic kidney disease progression and acute kidney injury occurrence.

In a real-world study from Taiwan evaluating 14,000 patients with type 2 diabetes and chronic kidney disease, patients initiating GLP-1 receptor agonists had a significantly higher risk of progressing to kidney replacement therapy compared to those on SGLT2 inhibitors over a 2.5-year median follow-up (hazard ratio 1.39; 95 percent CI 1.19–1.63)[21]. This difference was especially pronounced among patients with estimated glomerular filtration rate less than 45 or urine albumin-to-creatinine ratio greater than or equal to 300 milligrams per gram, populations at highest risk for kidney disease progression. However, when it came to overall mortality, there was no significant difference between the two groups. These findings emphasize that SGLT2 inhibitors may be more effective than GLP-1 receptor agonists in delaying progression to kidney failure, particularly in patients with more advanced chronic kidney disease or heavy albuminuria. Notably, secondary outcomes examining albuminuria and mortality were slightly reduced in GLP-1 receptor agonist initiators, suggesting that the two drug classes offer complementary renal protections through different mechanisms.

Atherosclerotic Cardiovascular Disease Phenotypes

A systematic review and meta-analysis examining twenty-six randomized controlled trials with 151,789 patients investigated the comparative cardiovascular effectiveness of GLP-1 receptor agonists and SGLT2 inhibitors across diverse atherosclerotic cardiovascular disease phenotypes[22]. Both drug classes significantly reduced MACE rates in atherosclerotic cardiovascular disease patients overall (risk ratio 0.85; 95 percent CI 0.80–0.91 for both). However, GLP-1 receptor agonists showed particular effectiveness in peripheral artery disease (risk ratio 0.86; 95 percent CI 0.76–0.98) and post-acute cardiovascular events defined as patients with established atherosclerotic cardiovascular disease or recent acute cardiovascular events (risk ratio 0.90; 95 percent CI 0.83–0.97). In atherosclerotic cardiovascular disease with heart failure, both drug classes reduced MACE, with GLP-1 receptor agonists demonstrating a risk ratio of 0.73 (95 percent CI 0.63–0.84) and SGLT2 inhibitors a risk ratio of 0.86 (95 percent CI 0.78–0.95). Notably, SGLT2 inhibitors significantly reduced MACE in atherosclerotic cardiovascular disease with chronic kidney disease (risk ratio 0.84; 95 percent CI 0.72–0.99), particularly in patients with severe albuminuria defined as urine albumin-to-creatinine ratio greater than 300 milligrams per gram (risk ratio 0.61; 95 percent CI 0.37–0.99).

These findings underscore that GLP-1 receptor agonists and SGLT2 inhibitors exhibit distinct cardiovascular effectiveness profiles across atherosclerotic cardiovascular disease phenotypes, with GLP-1 receptor agonists showing particular benefits in peripheral artery disease and post-acute cardiovascular events, while SGLT2 inhibitors demonstrate unique advantages in atherosclerotic cardiovascular disease with comorbid chronic kidney disease. Both are effective in heart failure, suggesting that tailored treatment strategies should account for the predominant atherosclerotic cardiovascular disease manifestation and comorbidities present in individual patients.

Combination Therapy: Evidence for Additive Cardiovascular Benefits

Rationale for Combined SGLT2i and GLP-1RA Treatment

The complementary mechanistic profiles of SGLT2 inhibitors and GLP-1 receptor agonists have generated substantial interest in combination therapy as a strategy for further reducing residual cardiovascular and renal risk in patients with type 2 diabetes[23][24]. SGLT2 inhibitors exert their cardiovascular and renal protective effects primarily through hemodynamic and metabolic mechanisms including natriuresis, osmotic diuresis, induction of a fasting-like state, and metabolic reprogramming, while GLP-1 receptor agonists work via anti-atherogenic and anti-inflammatory mechanisms that include improvements in endothelial function, blood pressure reduction, and sustained weight loss. This complementary mechanistic profile provides a strong biological rationale for combining these two classes to achieve additive cardiovascular and renal benefits.

Evidence supporting combination therapy comes from subgroup meta-analyses of cardiovascular outcomes trials involving populations with type 2 diabetes. A meta-analysis involving more than 70,000 participants with type 2 diabetes (SMART-C collaborative analysis) found that the cardiovascular benefits of SGLT2 inhibitors, including reductions in major adverse cardiovascular events, cardiovascular death, hospitalization for heart failure, and chronic kidney disease progression, were consistent regardless of whether patients were receiving a GLP-1 receptor agonist at baseline[23]. Similarly, a subgroup meta-analysis of cardiovascular outcomes trials with GLP-1 receptor agonists reported that the reduction in major adverse cardiovascular events was consistent regardless of whether participants were already being treated with an SGLT2 inhibitor at baseline[23]. These findings suggest that the benefits of one drug class are maintained and potentially amplified when combined with the other class, supporting the premise that combination therapy could produce additive cardiovascular and kidney benefits.

A meta-analysis of eighteen cohort studies with more than one million participants concluded that combining an SGLT2 inhibitor with a GLP-1 receptor agonist is associated with better cardiovascular, heart failure, and kidney outcomes compared to monotherapy[23]. Evidence suggests that combining SGLT2 inhibitors and GLP-1 receptor agonists improves metabolic outcomes including hemoglobin A1c, body weight, and blood pressure, with more important implications for addressing residual cardiovascular risk particularly in high-risk populations including those with established atherosclerotic cardiovascular disease or chronic kidney disease. A study on the cardiovascular effect of GLP-1 agonists and SGLT2 inhibitors and their combination on endothelial function, arterial stiffness, and left ventricular deformation in patients with type 2 diabetes with high or very high cardiovascular risk or heart failure with preserved ejection fraction hypothesized that endothelial function, arterial stiffness, and left ventricular deformation would be improved in patients treated with the combination of GLP-1 agonist and SGLT2 inhibitor compared to either agent alone or the combination of insulin and other antidiabetic tablets[25].

Safety and Clinical Implementation Considerations

While combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists holds promise for addressing residual cardiovascular risk in type 2 diabetes, its optimal use requires nuanced consideration of patient subpopulations, safety profiles, and cost-effectiveness[23]. Evidence supports significant benefits in individuals with high cardiorenal risk, though barriers such as adverse effects particularly in older individuals, underutilization in disadvantaged groups, and economic challenges may limit widespread adoption. Current clinical practice recommendations acknowledge a potential additive cardiovascular and kidney benefit from using both a GLP-1 receptor agonist and an SGLT2 inhibitor, though the accompanying treatment algorithms do not explicitly recommend combination therapy as first-line. The American Diabetes Association supports a multifactorial approach to reducing cardiovascular risk and diabetes-related complications emphasizing the importance of managing glycemic control, blood pressure, and lipid levels alongside incorporating therapies with proven cardiovascular and kidney benefits, which aligns with the concept that reducing cardiovascular risk in people with type 2 diabetes often requires multiple interventions to address various risk factors simultaneously.

Safety Profiles and Adverse Effects

GLP-1 Receptor Agonist Safety Considerations

GLP-1 receptor agonists are generally well-tolerated medications with favorable long-term safety profiles in cardiovascular outcomes trials[26]. The most common adverse effects are gastrointestinal in nature and include nausea, vomiting, diarrhea, and constipation, which are more likely to occur when patients start the medication or when doses are increased. These gastrointestinal adverse effects frequently lead to treatment discontinuation, with the SELECT trial noting that study drug discontinuation was twice as common in the semaglutide arm compared to placebo, with discontinuation primarily due to gastrointestinal intolerance. The SUSTAIN-6 trial similarly noted that more patients discontinued semaglutide treatment because of adverse events, mainly gastrointestinal, though serious adverse events occurred in a similar proportion of patients in both groups.

A serious safety concern that has generated clinical discussion is the potential for pancreatitis with GLP-1 receptor agonist use, though this remains rare in the clinical trial setting. The FDA has issued warnings regarding acute pancreatitis in patients taking GLP-1 receptor agonists, though large cardiovascular outcomes trials have not demonstrated a significant excess of pancreatitis events. Additionally, there have been reports of thyroid C-cell tumors in animal studies with GLP-1 receptor agonists, leading to a black box warning regarding personal or family history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma as contraindications to GLP-1 receptor agonist therapy. Hypoglycemia risk is generally low with GLP-1 receptor agonists when used as monotherapy, but increases when these agents are combined with insulin or sulfonylureas. Patients must receive appropriate education regarding symptoms of hypoglycemia including tremor, sweating, tachycardia, anxiety, confusion, and loss of consciousness, with treatment requiring consumption of simple carbohydrates. A modest increase in heart rate has been observed with some GLP-1 receptor agonists, though this does not appear to translate into adverse clinical outcomes in cardiovascular trials.

SGLT2 Inhibitor Safety Considerations

SGLT2 inhibitors demonstrate favorable safety profiles in most clinical contexts, though several specific adverse effects warrant clinician awareness[27][58]. A meta-analysis of large randomized trials with SGLT2 inhibitors demonstrated that these drugs significantly increased the risk of diabetic ketoacidosis (risk ratio 2.57), genital infections (risk ratio 3.75), and volume depletion (risk ratio 1.14), with increased trends observed in the risk of fractures (risk ratio 1.07), lower limb amputations (risk ratio 1.21), and urinary tract infections (risk ratio 1.07)[27]. However, a meta-analysis of forty cohort studies highlighted that SGLT2 inhibitor administration was associated with an increased risk of diabetic ketoacidosis (hazard ratio 1.21) and genital tract infections (hazard ratio 2.72), while these drugs were not associated with an increased risk of lower limb amputation (hazard ratio 1.06) or bone fractures (hazard ratio 0.99), and the risk of hypoglycemia was actually reduced.

Euglycemic diabetic ketoacidosis, a particularly concerning but rare adverse effect, has been reported with SGLT2 inhibitor use and can be triggered by factors such as severe insulin deficiency, low carbohydrate diet, alcohol intake, dehydration, or severe illnesses. However, large randomized trials have not demonstrated an excess risk of ketoacidosis in well-monitored populations. The canagliflozin CANVAS program did identify an increased risk of lower limb amputations (primarily toe or metatarsal level) that was specific to this SGLT2 inhibitor, necessitating careful patient selection and avoidance in patients with significant peripheral vascular disease or previous amputation.

Urogenital infections, both urinary tract infections and genital mycotic infections, occur with increased frequency in SGLT2 inhibitor users due to glycosuria and elevated urine glucose levels predisposing patients to microbial growth[27][58]. A retrospective study in a tertiary care hospital showed that 16.6 percent of patients on SGLT2 inhibitors presented with one or more episodes of genital mycotic infections while 3.3 percent developed urinary tract infections. However, a population-based cohort study assessing the risk of severe urinary tract infections in type 2 diabetic patients initiating SGLT2 inhibitors compared to those initiating dipeptidyl peptidase-4 inhibitors or GLP-1 receptor agonists found that the risk of severe urinary tract infections among patients initiating SGLT2 inhibitors was similar to that among patients initiating GLP-1 receptor agonists (hazard ratio 0.72). Notably, in routine clinical care, SGLT2 inhibitor initiation is not associated with increased risk of urinary tract infection compared with GLP-1 receptor agonist initiation, though early genital tract infection risk is elevated.

Implementation Challenges and Health Equity Considerations

Disparities in Medication Uptake

Despite strong evidence supporting the cardiovascular and renal benefits of SGLT2 inhibitors and GLP-1 receptor agonists, significant racial and ethnic disparities exist in the uptake and utilization of these medications[57]``[60]. A study examining racial and ethnic disparities in the uptake of SGLT2 inhibitors and GLP-1 receptor agonists found that Black participants with heart failure, atherosclerotic cardiovascular disease, chronic kidney disease, or no recorded cardiorenal conditions had 35, 33, 32, and 24 percent lower odds of initiating SGLT2 inhibitors respectively compared to White participants[57]. Similar patterns were observed for GLP-1 receptor agonist uptake among Black participants. By contrast, Hispanic participants had similar odds of SGLT2 inhibitor initiation in the heart failure and chronic kidney disease cohorts as White participants but 6 percent lower odds in the atherosclerotic cardiovascular disease cohort. Participants from Black and Hispanic backgrounds had greater odds than White participants of initiating dipeptidyl peptidase-4 inhibitors, which confer no cardiorenal benefits, across all cohorts.

The disparities in SGLT2 inhibitor initiation were most prominent in the earlier study years prior to 2016 for all cohorts, with Black participants having 50 to 60 percent lower odds of initiation than White participants, though these differences attenuated in a linear fashion year-on-year, though they did not dissipate entirely[57]. By 2019, Black participants with heart failure, atherosclerotic cardiovascular disease, and chronic kidney disease still had 17, 18, and 17 percent lower odds of SGLT2 inhibitor initiation respectively than White participants. These disparities remained despite adjusting for social determinants of health, suggesting additional determinants beyond socioeconomic factors influence medication prescribing patterns.

Cost Barriers and Treatment Access

A major barrier to widespread utilization of SGLT2 inhibitors and GLP-1 receptor agonists is their substantial cost, with out-of-pocket expenses significantly influencing treatment initiation. A nationwide cohort study of more than 80,000 older adults with type 2 diabetes and established cardiovascular disease covered by Medicare Advantage and commercial plans found that those in the highest quartile of out-of-pocket costs were 13 and 20 percent less likely to initiate a GLP-1 receptor agonist or SGLT2 inhibitor respectively when compared with those in the lowest quartile of out-of-pocket costs[59]. In the most comprehensive model adjusting for demographic, comorbidities, insurance type, and presence of hemoglobin A1c, the hazard ratios were 0.87 (95 percent CI 0.82–0.94) for GLP-1 receptor agonists and 0.80 (95 percent CI 0.73–0.88) for SGLT2 inhibitors when comparing highest to lowest out-of-pocket cost quartiles. This means that among older adults with type 2 diabetes and established cardiovascular disease, patients in the highest out-of-pocket cost quartile received intensification to guideline-recommended therapies a median of 3 to 6 months later than patients in the lowest out-of-pocket cost quartile. Such delays may reduce the potential impact of these medications on important clinical outcomes and result in higher downstream costs associated with treating cardiovascular and kidney disease complications.

Current Guidelines and Clinical Recommendations

The American Diabetes Association 2025 Standards of Care in Diabetes reflect the paradigm shift toward using SGLT2 inhibitors and GLP-1 receptor agonists for cardiovascular and renal risk reduction independent of glycemic control needs[28]. New recommendations include consideration of continuous glucose monitoring for adults with type 2 diabetes on glucose-lowering agents other than insulin, guidance on actions to take during circumstances of medication unavailability such as medication shortages, and additional guidance on the use of GLP-1 receptor agonists beyond weight loss for heart and kidney health benefits. Recommendation 9.12 was added to recommend use of GLP-1 receptor agonists with demonstrated benefits in individuals with type 2 diabetes, symptomatic heart failure with preserved ejection fraction, and obesity. Recommendation 9.13 was revised to recommend use of either SGLT2 inhibitor or GLP-1 receptor agonist with demonstrated benefits in individuals with type 2 diabetes and chronic kidney disease, acknowledging that while SGLT2 inhibitors generally offer superior renal protection, GLP-1 receptor agonists provide important alternative benefits particularly for weight loss and atherosclerotic event prevention.

The integration of lifestyle interventions with pharmacotherapy has become increasingly recognized as critical for optimal outcomes. A recent study examining more than 63,000 military veterans with type 2 diabetes found that those taking GLP-1 receptor agonist medications and adhering to at least six healthy lifestyle habits had a 50 percent lower risk of major adverse cardiovascular events compared to veterans with lower adherence to healthy lifestyle habits who were receiving standard diabetes care without GLP-1 receptor agonist medication[29]. The risk of major cardiovascular events was 20 percent lower among veterans taking GLP-1 receptor agonist medications compared to those not taking these medications, which is consistent with prior research findings. These data emphasize that medication therapy should not be viewed as a substitute for lifestyle modifications but rather as a complementary component of a comprehensive cardiovascular risk reduction strategy.

Conclusion

In summary, extensive clinical trial evidence demonstrates that both glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors represent breakthrough therapies for reducing cardiovascular risk in patients with type 2 diabetes, though they achieve these benefits through distinct mechanistic pathways and demonstrate differential efficacy across various clinical phenotypes. Meta-analytical data from twelve randomized controlled trials involving 99,261 high-risk patients indicate that both drug classes significantly reduce major adverse cardiovascular events compared to placebo, with indirect comparisons showing a nominally greater MACE reduction with GLP-1 receptor agonists. However, SGLT2 inhibitors demonstrate pronounced advantages in reducing hospitalization for heart failure and protecting kidney function, while GLP-1 receptor agonists excel in preventing atherosclerotic events particularly stroke and in promoting significant weight loss. SGLT2 inhibitors provide the most pronounced benefits in heart failure with both reduced and preserved ejection fraction, while GLP-1 receptor agonists offer important complementary mortality and cardiovascular benefits in this population. In chronic kidney disease populations, SGLT2 inhibitors appear superior for slowing chronic kidney disease progression and reducing acute kidney injury occurrence, particularly in patients with advanced chronic kidney disease or heavy albuminuria, though GLP-1 receptor agonists provide additional mortality benefits.

The distinct secondary outcome profiles of these drug classes support their use as complementary rather than interchangeable therapies, with treatment selection guided by individual patient phenotypes, predominant cardiovascular or renal comorbidities, and specific treatment goals. For patients with established heart failure or advanced chronic kidney disease, SGLT2 inhibitors should generally be prioritized based on the robust evidence for heart failure hospitalization reduction and chronic kidney disease slowing. For patients with established atherosclerotic cardiovascular disease, peripheral artery disease, or strong indications for weight loss, GLP-1 receptor agonists offer documented benefits. Current guidelines increasingly recommend considering both drug classes for high-risk patients, with growing evidence supporting upfront combination therapy to further reduce residual cardiovascular and renal risk. Implementation challenges including disparities in medication uptake among racial and ethnic minorities and cost-related treatment delays necessitate focused efforts to improve equitable access to these life-changing therapies. Future research should continue to evaluate optimal combination strategies, identify patient phenotypes most likely to benefit from each class, and address the persistent barriers to widespread utilization of these evidence-based therapies to maximize their population health impact in reducing the enormous burden of cardiovascular and kidney disease in type 2 diabetes.

Fuentes

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC12849425/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC10932840/
  3. https://www.acc.org/-/media/Non-Clinical/Files-PDFs-Excel-MS-Word-etc/Tools-and-Practice-Support/Quality-Programs/Diabetes-Roundtable-2017/SupplementalReading/4-Semaglutide-and-Cardiovascular-Outcomes-in-Patients-with-Type-2-Diabetes-SUSTAIN6.pdf
  4. https://diabetesjournals.org/care/article/43/7/1546/35543/Cardiovascular-Risk-Reduction-With-Liraglutide-An
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC7440910/
  6. https://pmc.ncbi.nlm.nih.gov/articles/PMC11439431/
  7. https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2023/11/09/15/04/select
  8. https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2015/09/17/10/11/EMPA-REG-OUTCOME
  9. https://pubmed.ncbi.nlm.nih.gov/26378978/
  10. https://pubmed.ncbi.nlm.nih.gov/31196815/
  11. https://timi.org/declare-timi-58/
  12. https://pubmed.ncbi.nlm.nih.gov/28605608/
  13. https://newsroom.heart.org/news/glp-1-sglt2-medications-may-lower-stroke-survivors-risk-of-future-heart-attack-stroke
  14. https://pubmed.ncbi.nlm.nih.gov/38881421/
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC12799618/
  16. https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC12664052/
  18. https://newsroom.heart.org/news/healthy-lifestyle-combined-with-newer-diabetes-medications-lowered-cardiovascular-risk
  19. https://diabetesjournals.org/care/article/48/Supplement_1/S6/157564/Summary-of-Revisions-Standards-of-Care-in-Diabetes
  20. https://pubmed.ncbi.nlm.nih.gov/41557360/
  21. https://ajkdblog.org/2025/10/15/glp1-receptor-agonists-vs-sglt2-i-in-preventing-ckd-in-t2dm-an-interview/
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC11942771/
  23. https://www.jci.org/articles/view/167700
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC7755023/
  25. https://clinicaltrials.gov/study/NCT03878706
  26. https://pubmed.ncbi.nlm.nih.gov/28432726/
  27. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2805937
  28. https://www.tctmd.com/news/benefits-sglt2-inhibitors-hf-affirmed-large-real-world-study
  29. https://diabetes.org/newsroom/press-releases/american-diabetes-association-releases-standards-care-diabetes-2025
  30. https://clinicaltrials.gov/study/NCT03939624
  31. https://www.goodrx.com/conditions/diabetes-type-2/glp-1-vs-sglt2
  32. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2838602
  33. https://clinicaltrials.gov/study/NCT07198191
  34. https://diabetesjournals.org/diabetes/article/74/5/672/157860/Comparison-of-the-Effects-of-SGLT-2i-Versus-GLP
  35. https://clinicaltrials.gov/study/NCT01032629
  36. https://clinicaltrials.gov/study/NCT01720446
  37. https://diabetesjournals.org/care/article/48/5/846/158048/Cardiovascular-and-Kidney-Outcomes-and-Mortality
  38. https://journals.viamedica.pl/clinical_diabetology/article/download/DK.a2022.0037/68594
  39. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2822209
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC12861902/
  41. https://utsouthwestern.elsevierpure.com/en/publications/comparative-efficacy-safety-and-cardiovascular-outcomes-with-once/
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC11320168/
  43. https://ccs.ca/guideline/cardiorenal-2022/2-integration-of-sglt2i-in-the-management-of-patients-with-ckd/
  44. https://pubmed.ncbi.nlm.nih.gov/30615985/
  45. https://www.pharmacytimes.com/view/apha-2025-glp-1-receptor-agonists-vs-sglt2-inhibitors-show-varied-benefit-for-cardiovascular-outcomes-in-patients-with-diabetes
  46. https://www.acc.org/Latest-in-Cardiology/Journal-Scans/2021/10/13/15/54/Sodium-Glucose-Cotransporter-2
  47. https://pubmed.ncbi.nlm.nih.gov/36508493/
  48. https://www.glucagon.com/pdfs/UssherNRC2023.pdf
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC10870536/
  50. https://www.clinicaladvisor.com/news/kidney-outcomes-better-with-sglt2-inhibitors-vs-glp-1-receptor-agonists-in-diabetes/
  51. https://academic.oup.com/ehjcvp/article/11/2/174/8005548
  52. https://diabetesjournals.org/care/article/48/11/1904/163403/Impact-of-Baseline-GLP-1-Receptor-Agonist-Use-on
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC9947091/
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC11663158/
  55. https://diabetesjournals.org/care/article/48/6/945/158055/Risk-of-Urogenital-Infections-in-People-With-Type
  56. https://scholarlycommons.henryford.com/publichealthsciences_articles/535/

Respuesta generada por inteligencia artificial a partir de las fuentes citadas. Verifica las fuentes antes de aplicarla.

¿Tienes una pregunta sobre tu propio caso? Itaca responde con fuentes en segundos.

Hacer una pregunta

Más preguntas sobre diabetes mellitus tipo 2